<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mitochondrial disorders: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mitochondrial disorders: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mitochondrial disorders: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erin O'Ferrall, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mitochondrial diseases are present with a wide range of clinical phenotypes. The organ systems most reliant on aerobic metabolism are preferentially affected. Myopathy may be the sole or main sign, or merely an incidental finding associated with a multisystemic illness. Involvement of the nervous system in general (referred to as mitochondrial encephalomyopathy) is common. When skeletal muscle is affected, either alone or with central nervous system disease, the term mitochondrial myopathy is used. Although mitochondria are known to play a role in diverse cellular functions including redox balance, apoptosis, fatty acid oxidation, and calcium homeostasis, this review will focus on the treatment of mitochondrial diseases due to pathologic dysfunction of the mitochondrial respiratory chain.</p><p>The following groups illustrate the different ways mitochondrial myopathies can present clinically:</p><p class="bulletIndent1"><span class="glyph">●</span>As chronic progressive external ophthalmoplegia (with or without mild proximal muscle weakness) or Kearns-Sayre syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>As an isolated myopathy with or without exercise intolerance and/or myalgia</p><p class="bulletIndent1"><span class="glyph">●</span>As a severe myopathy or encephalomyopathy of infancy and childhood</p><p class="bulletIndent1"><span class="glyph">●</span>As a predominantly multisystem disease (eg, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes [MELAS])</p><p></p><p>A certain degree of overlap exists between all these entities. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>This topic will discuss symptomatic management of mitochondrial myopathies and review the evidence for exercise and pharmacologic agents, concentrating on those with more robust or more promising evidence. Finally, strategies for gene therapy will be introduced. Other aspects of mitochondrial myopathies are discussed separately. (See  <a class="medical medical_review" href="/d/html/5148.html" rel="external">"Mitochondrial regulation and functions"</a> and  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SUPPORTIVE CARE AND MONITORING</span><span class="headingEndMark"> — </span>The mainstay of treatment for patients with mitochondrial myopathies is supportive. Depending on the degree of impairment and the extent of neurologic involvement, the following evaluations and interventions may be indicated [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory </strong>– Respiratory evaluation and management is often a life-saving or life-sustaining measure in patients with chronic respiratory failure. A discussion of respiratory or sleep-related symptoms should occur regularly with the patient, family, and caregivers. Pulmonary function tests should be obtained at baseline and again as clinically indicated when symptoms appear. Interventions include noninvasive measures such as continuous positive air pressure (CPAP) and bilevel positive air pressure (BiPAP). Some patients may eventually require tracheostomy [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epilepsy</strong> – Standard anticonvulsant therapy can be used to control seizures. An exception is that <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> and its derivatives should be avoided if possible because they inhibit the biosynthesis of carnitine, potentially leading to impaired mitochondrial beta-oxidation and fatty acid metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – Cardiac involvement occurs in up to 30 percent of patients with mitochondrial disease [<a href="#rid4">4</a>]. Therefore, assessment for cardiomyopathy and conduction defects is important.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ophthalmologic </strong>– Ptosis can be treated with frontalis muscle-eyelid suspension, levator palpebrae resection, eyelid crutches, or blepharoplasty. Cataracts are treated with intraocular lens replacement. Ophthalmoplegia usually does not require any specific intervention but can be addressed by glasses with corrective prisms when accompanied by significant diplopia. Strabismus surgery is also an option if the degree of ophthalmoplegia is stable for at least six months on serial measurements [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Audiologic </strong>– Sensorineural hearing loss can be addressed with cochlear implants. Aminoglycosides should be avoided [<a href="#rid6">6</a>]. (See <a class="local">'Potentially toxic agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine</strong> – Diabetes mellitus can be managed with dietary modification, oral agents, or insulin as appropriate. However, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> should be avoided because it has been associated with lactic acidosis. (See  <a class="medical medical_review" href="/d/html/296.html" rel="external">"Metformin poisoning", section on 'Lactic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rehabilitative services</strong> – Multidisciplinary speech, physical, and occupational therapy can be helpful for patients with central nervous system deficits such as dysarthria, dysphagia, weakness, spasticity, and/or ataxia [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopmental assessment</strong> – Many mitochondrial disorders can lead to neuroregression, characterized by a loss of developmental and cognitive abilities [<a href="#rid2">2</a>]. Patients should have baseline cognitive, behavioral, and developmental evaluations, along with appropriate intervention, as well as repeated evaluations as needed to track their function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver and pancreas</strong> – Certain mitochondrial disorders are associated with an increased risk of liver dysfunction and failure [<a href="#rid2">2</a>]. Annual transaminase levels are recommended, with more thorough evaluation if transaminases are elevated or if the patient develops symptoms. Note that many medications used to treat epilepsy are metabolized by the liver and may be affected by liver dysfunction.</p><p></p><p class="bulletIndent1">Screening for pancreatic insufficiency is warranted for patients with mitochondrial disorders and unexplained diarrhea, steatorrhea, or growth failure [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – For patients with dysphagia, diabetes, weight loss, or exocrine pancreas dysfunction, consultation with a nutritionist is indicated. A gastrostomy tube may be required if severe dysphagia is present. Specific diets may be used depending on both the nutritional status of the patient and the specific biochemical defect present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal and adrenal</strong> – Renal function can be impaired due to proximal or distal renal tubule acidosis or as a complication of diabetes and may lead to significant electrolyte abnormalities. Patients should be monitored for electrolyte balance including sodium, potassium, calcium, magnesium, and phosphate. Electrolyte abnormalities should trigger an evaluation of renal tubular and adrenal function [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Although adrenal failure is not common overall in mitochondrial disease, it does occur in Kearns-Sayre syndrome and can be life threatening.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling</strong> – As defined by the National Society of Genetic Counselors, genetic counseling is the process of helping people understand and adapt to the medical, psychologic, and familial implications of genetic contributions to disease [<a href="#rid8">8</a>]. Inheritance of mitochondrial diseases may be maternal, autosomal dominant, autosomal recessive, or X-linked. Transmission can be complex due to several factors including heteroplasmy, denoting variable levels of mitochondrial pathogenic variants in different tissues (see  <a class="medical medical_review" href="/d/html/5148.html" rel="external">"Mitochondrial regulation and functions"</a>). Parents of severely affected children and affected patients of reproductive age should be offered genetic counseling to help with reproductive planning.</p><p></p><p class="headingAnchor" id="H1238982354"><span class="h1">NONSPECIFIC TREATMENTS</span><span class="headingEndMark"> — </span>There is no proven effective therapy for the primary mitochondrial disorders. Nonspecific empiric treatments include antioxidants and cofactor supplements (see <a class="local">'Antioxidant and cofactor supplements'</a> below), exercise (see <a class="local">'Exercise'</a> below), and dietary therapies (see <a class="local">'Ketogenic dietary therapy'</a> below).</p><p>Pharmacologic strategies that have been tested for these conditions include the use of respiratory chain cofactors, treatment with antioxidants, and agents that correct secondary biochemical deficits. Much of the evidence comes from single case reports and small open-label studies. A systematic review published in 2012 identified 12 randomized controlled trials that evaluated pharmacologic agents for mitochondrial diseases, but no clear evidence was found to support the use of any intervention [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2496373235"><span class="h2">Antioxidant and cofactor supplements</span></p><p class="headingAnchor" id="H3515097011"><span class="h3">Our approach</span></p><p class="bulletIndent1"><span class="glyph">●</span>Although not established as effective for mitochondrial disorders, our typical regimen for adults and adolescents is a multivitamin, coenzyme Q10 (CoQ10; 400 mg daily), creatine (10 g daily), L-carnitine (levocarnitine) supplementation (990 mg daily in three divided doses), folate (1 mg daily), and B complex vitamins (eg, vitamin B-100 complex, one tablet daily). We add vitamin D and vitamin B12 supplementation <strong>if</strong> measured to be deficient in the serum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children, some experts advocate the following regimen: CoQ10 (10 to 20 mg/kg per day), L-carnitine supplementation (50 mg/kg per day), and vitamine B2 (<a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>) 100 to 400 mg per day; other experts include <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> (50 to 100 mg per day).</p><p></p><p class="headingAnchor" id="H1156494899"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>Mitochondrial diseases in general result in an increase in oxidative stress and higher levels of reactive oxygen species [<a href="#rid10">10</a>]. This may cause damage to the cell membrane through lipid peroxidation.</p><p>Several antioxidants have been used to treat patients with mitochondrial myopathies, with the rationale that scavenging reactive oxygen species would lead to clinical improvement. The list includes CoQ10 (antioxidant in its reduced form), idebenone (a synthetic analog of CoQ10), <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>, alpha-lipoic acid (or dihydrolipoate, its reduced form), and compounds with antioxidant activity (eg, L-carnitine, <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>) [<a href="#rid11">11</a>].</p><p>Succinate, <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>, <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a>, CoQ10, creatine monophosphate, and alpha-lipoic acid participate as cofactors in the electron transport chain enzymes  (<a class="graphic graphic_figure graphicRef67253" href="/d/graphic/67253.html" rel="external">figure 1</a>). Supplementation is thought to enhance the activity of these enzymes when they are deficient [<a href="#rid12">12</a>].</p><p>Levels of carnitine, creatine, and folate are decreased in patients with mitochondrial disorders, although the exact mechanisms are unclear [<a href="#rid13">13,14</a>]. Given the relatively harmless effect of their supplementation, they are often given as part of a "mitochondrial cocktail" to patients. However, there is no compelling evidence that supplementation of these agents produces a clinically important benefit.</p><p class="headingAnchor" id="H79037579"><span class="h3">Specific supplements</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-lipoic acid</strong> – Alpha-lipoic acid is an antioxidant that is used in some mitochondrial disease "cocktails," but clinical data are sparse [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carnitine</strong> – L-carnitine has not been studied in controlled trials in the context of primary mitochondrial respiratory chain disorders. However, <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">carnitine supplementation</a> can be almost curative in carnitine transporter deficiency, also called primary systemic carnitine deficiency, which typically presents in childhood with dilated cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/115918.html" rel="external">"Specific fatty acid oxidation disorders", section on 'Carnitine transporter deficiency'</a>.)</p><p></p><p class="bulletIndent1">We suggest treatment with L-carnitine because it is generally safe and may help to correct an underlying deficiency of free carnitine [<a href="#rid12">12</a>]. While we recommend measuring total and free carnitine levels on a regular basis, the suggested dose for adolescents and adults is L-carnitine supplementation 1000 mg daily in the morning. The suggested dose for children is 50 to 100 mg/kg per day, given in four divided doses [<a href="#rid17">17</a>]. Older patients on carnitine who are at high risk for or are known to have coronary artery disease should be monitored in consultation with cardiology, since some studies suggest a theoretical risk of progression due to the trimethylamine-N-oxide metabolite of carnitine [<a href="#rid18">18,19</a>]. However, other reports suggest that higher L-carnitine levels are associated with a lower risk of cardiovascular events [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coenzyme Q10</strong> – Given the evidence of modest benefit in one trial and the lack of serious side effects, we suggest treatment with CoQ10 for most patients with mitochondrial disorders in which CoQ10 levels are not known or are not reduced. The suggested dose is 5 mg/kg per day for infants and children and 400 mg daily for adolescents and adults. Higher doses are suggested for patients who have mitochondrial disease with CoQ10 deficiency. (See <a class="local">'CoQ10 deficiency'</a> below.)</p><p></p><p class="bulletIndent1">CoQ10 has been evaluated in small randomized controlled trials, with equivocal results. A placebo-controlled blinded crossover design evaluated 30 patients with various mitochondrial encephalomyopathies, including 15 with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) and 11 with chronic progressive external ophthalmoplegia [<a href="#rid21">21</a>]. Treatment with CoQ10 (1200 mg daily) for 60 days did <strong>not</strong> lead to improvement in clinical measures such as grip strength, activities of daily living, or quality of life, but it did increase oxygen uptake (VO<sub>2</sub>) after 15 minutes of exercise and attenuated the rise in lactate.</p><p></p><p class="bulletIndent1">Another double-blind crossover trial evaluated eight patients with various mitochondrial encephalomyopathies, including three with MELAS, who took CoQ10 (160 mg/day) for three months followed by a one month washout period and then placebo for one month, or placebo for one month followed by CoQ10 for three months [<a href="#rid22">22</a>]. CoQ10 treatment led to a statistically significant increase in a global scale of muscle strength and an increase in serum levels of CoQ10.</p><p></p><p class="bulletIndent1">The earliest trial evaluated 17 patients with chronic progressive external ophthalmoplegia and was negative [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">It is unlikely there is a different response to CoQ10 between the reduced form (ubiquinol) and the oxidized form (ubiquinone), though CoQ10 bioavailability in humans is highly variable [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Creatine</strong> – Given the evidence from at least one controlled trial of possible modest benefit, as well as its relative lack of side effects, we suggest creatine to most of our patients with mitochondrial encephalomyopathies. The optimal creatine dose is uncertain. For adolescents and adults, one trial used 10 g daily for the first two weeks, followed by 4 g daily for maintenance [<a href="#rid25">25</a>]. However, cramps can be a problem at such high doses. Therefore, we usually start creatine at 4.5 g daily given in three divided doses and titrate it up as tolerated, with a maximum total dose of 10 g per day. For infants and young children, creatine doses from 0.08 to 0.35 g/kg daily have been used [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">However, the evidence for benefit is inconsistent. In a placebo-controlled crossover trial involving six patients (five with MELAS and one with a mitochondrial myopathy), treatment with creatine (10 g/day for two weeks followed by 4 g/day for one week) resulted in improvement in some variables, including a statistically significant 20 percent increase in hand grip strength [<a href="#rid25">25</a>]. However, there was no improvement in activities of daily living.</p><p></p><p class="bulletIndent1">A second placebo-controlled crossover trial involving 16 patients with a mitochondrial disorder (including 13 with chronic progressive external ophthalmoplegia) found no significant benefit after four weeks with high-dose creatine (20 g daily) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">In another placebo-controlled crossover trial that analyzed results from 16 patients with various mitochondrial disorders, treatment with a combination of creatine, CoQ10, and alpha-lipoic acid resulted in a reduction of serum lactate and a reduction in the decline of peak ankle dorsiflexion strength [<a href="#rid15">15</a>]. However, there was no effect on pulmonary function or on peak handgrip or knee extension strength.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Folate </strong>– Folate is part of a metabolic pathway that provides methyl groups in the biosynthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), hormones, and neurotransmitters. Folate deficiency can alter gene expression of mitochondrial DNA.</p><p></p><p class="bulletIndent1">Cerebral folate deficiency is a condition in which 5-methyltetrahydrofolate levels are low in the cerebrospinal fluid while peripheral folate status is normal [<a href="#rid28">28,29</a>]. Cerebral folate deficiency has been associated with several mitochondrial disorders including Kearns-Sayre syndrome; the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP); Leigh syndrome; and mitochondrial encephalomyopathies [<a href="#rid30">30</a>]. Cerebral folate deficiency is not limited to mitochondrial disease and occurs with other disorders, including an autoimmune form with folate-receptor blocking antibodies, Rett syndrome, and Aicardi-Goutières Syndrome [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">Some authors suggest high-dose folinic acid supplementation (from 0.5 to 8 mg/kg per day) for mitochondrial disease, although this is based only on reports of improvement in a small number of cases [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin B2</strong> – Vitamin B2 (<a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>) replacement therapy (10 to 50 mg/kg day in children and up to 1500 mg/day in adults) was associated with stable or substantially improved function in case reports of patients with riboflavin transporter deficiency, and there were no observed adverse effects [<a href="#rid32">32</a>]. However, there is no evidence for its use in other mitochondrial diseases.</p><p></p><p class="headingAnchor" id="H4213903390"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>We suggest routine, moderate-level aerobic exercise (eg, walking, running, cycling, or swimming) combined with regular mild resistance strength training for patients with mitochondrial disorders who can participate in physical activity.</p><p>Exercise appears to be beneficial in mitochondrial disorders [<a href="#rid11">11,33</a>]. Aerobic exercise has been associated with increased peak work, oxidative capacity, and mitochondrial volume [<a href="#rid34">34-37</a>]. In addition, aerobic exercise can prevent muscle deconditioning and decrease exercise intolerance [<a href="#rid38">38</a>].</p><p>There is also some evidence that the response to resistance training exercise can alter the proportion of mutant and wildtype mitochondrial DNA (ie, gene shifting) in regenerated muscle fibers by activating wildtype satellite cells [<a href="#rid36">36,39,40</a>]. However, it is not clear whether this is a viable strategy to reduce the burden of mutant mitochondrial DNA in muscle and thereby improve muscle function.</p><p class="headingAnchor" id="H4251290618"><span class="h2">Ketogenic dietary therapy</span><span class="headingEndMark"> — </span>Ketogenic dietary therapy (KDT) is an option for patients with mitochondrial disorders, particularly for patients with drug-resistant epilepsy, which is a common manifestation of mitochondrial dysfunction, and for patients with pyruvate dehydrogenase deficiency [<a href="#rid11">11</a>]. However, KDT is contraindicated in patients with mitochondrial DNA deletion-related myopathy [<a href="#rid41">41</a>]. When employed, KDT should be administered in the context of a multidisciplinary team including a nutritionist and with careful monitoring of blood sugar, electrolytes, cholesterol, bone density, and symptoms suggesting renal colic or constipation. Growth should also be monitored in pediatric patients.</p><p>The classic ketogenic diet is a high-fat, adequate-protein, low-carbohydrate diet that produces metabolic changes in plasma ketones, insulin, glucose, glucagon, and free fatty acids. Potential mechanisms of ketone body metabolism that may benefit patients with mitochondrial disorders include reduced levels of oxidative stress and increased levels of antioxidants and free radical scavengers [<a href="#rid41">41-43</a>].</p><p>A 2020 systematic review identified 17 reports of 20 patients with genetically proven mitochondrial disease using KDT that met inclusion criteria [<a href="#rid41">41</a>]. KDT was associated with seizure control of refractory epilepsy in 7 of 8 cases (temporary in 4), improved muscular symptoms in 3 of 10, and reversal of the clinical phenotype in 4 of 20 cases. However, in five adults with mitochondrial DNA deletion-related myopathy, KDT was stopped due to the development of rhabdomyolysis. Three patients with <em>POLG</em> pathogenic variants and Alpers syndrome died while on KDT, but their death was not considered related to KDT.</p><p>In a prospective open-label study of pediatric patients with mitochondrial disease and epilepsy, KDT was associated with a ≥50 percent reduction in seizures at three months in 9 of 22 patients (41 percent) [<a href="#rid44">44</a>]. A similar proportion withdrew from the study due to inability to tolerate or comply with KDT.</p><p>Patients with epilepsy and complex I mitochondrial disorders may be particularly responsive to KDT [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p class="headingAnchor" id="H915516981"><span class="h1">POTENTIALLY TOXIC AGENTS</span></p><p class="headingAnchor" id="H1542938571"><span class="h2">Drugs of concern</span><span class="headingEndMark"> — </span>A number of medications should be avoided if possible, or used with caution when necessary, for patients with mitochondrial disorders [<a href="#rid11">11,46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antiseizure medications:</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproic acid</a> and its derivatives</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">Zonisamide</a></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics:</p><p class="bulletIndent2"><span class="glyph">•</span>Aminoglycosides</p><p class="bulletIndent2"><span class="glyph">•</span>Antiretrovirals</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a></p><p class="bulletIndent2"><span class="glyph">•</span>Clevudine</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a></p><p class="bulletIndent1"><span class="glyph">●</span>Dichloroacetate</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a></p><p class="bulletIndent1"><span class="glyph">●</span>Statins</p><p class="bulletIndent1"><span class="glyph">●</span>Anesthetics:</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a></p><p></p><p class="headingAnchor" id="H2950728789"><span class="h2">Associated risks</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> increases the risk of liver failure and seizures including status epilepticus, particularly in patients with pathogenic variants in <em>POLG </em>[<a href="#rid46">46</a>]. Weaker evidence suggests that <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> may cause seizure aggravation [<a href="#rid11">11</a>]. <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> and <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a> are partial carbonic anhydrase inhibitors that can cause metabolic acidosis in some patients [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondria are susceptible to aminoglycosides and other antibiotics targeting the bacterial ribosome [<a href="#rid46">46</a>]. Aminoglycosides should be avoided in patients with multisystem mitochondrial disorders, because such patients are at increased risk of hearing loss. (See  <a class="medical medical_review" href="/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a> use is associated with a low risk of acute hepatitis, blood dyscrasia, and bone marrow suppression, so alternative agents are preferred for patients with systemic mitochondrial disorders affecting the liver or bone marrow, including mitochondrial DNA depletion syndromes and Pearson syndrome [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> and <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> increase the risk of lactic acidosis [<a href="#rid46">46</a>]. This may be particularly important for patients with mitochondrial disorders who have undetected cardiomyopathy, a condition that probably increases the risk of lactic acidosis. (See  <a class="medical medical_review" href="/d/html/296.html" rel="external">"Metformin poisoning", section on 'Lactic acidosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiretrovirals, clevudine, and statins increase the risk of myopathy, and patients with mitochondrial disorders may be particularly susceptible to myopathy associated with statin therapy [<a href="#rid11">11,46,48</a>]. (See  <a class="medical medical_review" href="/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a> and <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> are potential mitochondrial toxins, and patients with mitochondrial disorders may be at increased risk of developing propofol infusion syndrome [<a href="#rid48">48,49</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT OF INDIVIDUAL DISORDERS</span></p><p class="headingAnchor" id="H13"><span class="h2">CoQ10 deficiency</span><span class="headingEndMark"> — </span>Primary coenzyme Q10 (CoQ10) deficiency occurs in patients with disorders of CoQ10 biosynthesis, while secondary CoQ10 deficiency arises when a disorder of the mitochondrial respiratory chain reduces CoQ10 levels. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Coenzyme Q10 deficiency'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – We suggest high-dose oral CoQ10 treatment for patients with CoQ10 deficiency. Suggested CoQ10 dosing is 5 to 30 mg/kg daily (in three divided doses) for infants and children, 300 to 1500 mg daily for adolescents, and up to 2400 mg daily for adults [<a href="#rid50">50-53</a>].</p><p></p><p class="bulletIndent1">Although some patients with primary or secondary CoQ10 deficiency respond to CoQ10 replacement, it is not universally successful. In a 2022 systematic review that identified 89 patients with primary CoQ10 deficiency treated with oral CoQ10 supplementation, nonresponders made up 73 percent of the cases [<a href="#rid53">53</a>]. In the 27 percent with improvement, the response was only partial and frequently involved only a single symptom. CoQ10 supplementation was not associated with substantial adverse effects in patients with CoQ10 deficiency [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">However, limited observational evidence suggests that high-dose oral CoQ10 treatment is associated with clinically meaningful improvement in muscle function in some patients [<a href="#rid52">52,54-57</a>]. Furthermore, CoQ10 treatment can be life-saving in infants with encephalomyopathy [<a href="#rid12">12,50,51</a>]. On the other hand, central nervous system manifestations may be only partially reversible or may continue to progress despite treatment [<a href="#rid52">52,58,59</a>]. Anecdotal evidence suggests that treatment prior to the onset of overt neurologic symptoms (age 12 months in the reported case) can prevent neurologic involvement [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H2059818483"><span class="h2">Leigh syndrome</span><span class="headingEndMark"> — </span>Leigh syndrome (subacute necrotizing encephalomyelopathy) is characterized by progressive neurodegeneration, external ophthalmoplegia, seizures, lactic acidosis, and symmetric lesions in the basal ganglia or brainstem on magnetic resonance imaging (MRI). It most often presents in infancy or early childhood, although late childhood and adult onset have been reported. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Leigh syndrome'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There is no proven treatment for Leigh syndrome. However, patients with suspected Leigh syndrome should be treated with <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> (10 mg/kg) and <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> (20 mg/kg) daily, since biotin-thiamine-responsive basal ganglia disease (BTBGD) is a treatable condition that mimics Leigh syndrome [<a href="#rid60">60-62</a>].</p><p></p><p class="bulletIndent1">In addition to <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> and <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a>, it is also reasonable to treat Leigh syndrome empirically with a combination of antioxidant and oxidative phosphorylation cofactors, including CoQ10, <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">carnitine supplementation</a>, vitamin B2 (<a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>), alpha-lipoic acid, creatine monohydrate, and <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H2254465415"><span class="h2">LHON</span><span class="headingEndMark"> — </span>Leber hereditary optic neuropathy (LHON) is a maternally inherited bilateral subacute optic neuropathy that typically produces severe and permanent visual loss, typically in young males but increasingly recognized in females [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Leber hereditary optic neuropathy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Prior to treatment, patients with LHON should be referred to neuro-ophthalmology for clinical evaluation, management, and follow-up. Testing typically includes visual acuity, automated visual fields, and optical coherence tomography for analysis of the optic nerve head, retinal nerve fiber layer, and macular nerve fiber and ganglion cell layer [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There is no proven effective treatment for LHON. Idebenone (a synthetic analog of CoQ10) is approved in Europe for the treatment of visual impairment in adolescent and adult patients with LHON. Most of the data suggesting benefit are retrospective [<a href="#rid65">65-67</a>]. Idebenone was tested in a randomized, placebo-controlled, double-blind trial of 85 patients with LHON [<a href="#rid68">68</a>]. There was no benefit with idebenone by intention-to-treat analysis for the primary outcome (best recovery in visual acuity). However, there was a trend for improved vision, and a post hoc analysis suggested benefit for a subgroup of patients with discordant visual acuity between eyes at baseline. Where available, a one- to three-year trial of idebenone may be considered for symptomatic patients in conjunction with regular neuro-ophthalmologic testing as described above.</p><p></p><p class="bulletIndent1">Small studies have evaluated gene therapy for LHON, employing a viral vector to deliver a wildtype version of the defective gene. In an open-label study, five legally blind patients with LHON due to <em>ND4</em> pathogenic variants in mitochondrial DNA were treated with an intravitreal injection of an adeno-associated virus (AAV) vector containing the wildtype <em>ND4</em> gene [<a href="#rid69">69</a>]. No serious safety issues were identified during 90 to 180 days of follow-up. Two of the five participants experienced an improvement in vision in the first 90 days. Subsequent studies of gene therapy for LHON using intravitreal injections of AAV vectors found that the treatment is safe and well tolerated [<a href="#rid70">70-75</a>]. Although most of these studies were underpowered for efficacy, several reported improved visual acuity.</p><p></p><p class="headingAnchor" id="H14"><span class="h2">MELAS</span><span class="headingEndMark"> — </span>The syndrome of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is one of the most common mitochondrial disorders (see  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'MELAS'</a>), but no specific disease-modifying therapy is available.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – For suspected acute stroke-like episodes, evaluation involves blood studies to include serum lactate, brain MRI, electroencephalography (EEG), and additional tests as appropriate for the evaluation of acute stroke and seizure  (<a class="graphic graphic_table graphicRef139547" href="/d/graphic/139547.html" rel="external">table 1</a>) [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Stroke-like episodes in MELAS can be triggered by seizure, which causes energy depletion, neuronal injury, and breakdown of the blood-brain barrier, which in turn leads to vasogenic edema [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1">For patients with MELAS who have stroke-like episodes accompanied by seizure, a 2019 consensus statement recommends aggressive treatment with antiseizure medication using intravenous <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> (20 to 40 mg/kg, maximum 4500 mg) as first choice [<a href="#rid76">76</a>]. Other options are <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> (15 to 20 mg/kg with cardiac monitoring), phenobarbitone (10 to 15 mg/kg with respiratory monitoring), or <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a> (200 to 400 mg). The role of antiseizure medications is unclear for patients with no history of seizure-like events and no epileptiform activity on EEG. Some experts have also treated stroke-like episodes with urgent intravenous normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to maintain cerebral perfusion and with dextrose-containing fluids to provide an anabolic substrate [<a href="#rid78">78,79</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">Arginine</a> supplementation has been used as a strategy to treat patients with MELAS, both as an infusion in the acute phase of the stroke-like episodes and as an oral daily therapy [<a href="#rid80">80-82</a>]. However, evidence of efficacy is lacking. A systematic review of L-arginine treatment of stroke-like episodes in patients with mitochondrial disease identified 37 articles (zero randomized controlled trials, three nonrandomized open-label studies, one retrospective cohort study, and 33 case reports or case series) with a total of 91 patients [<a href="#rid83">83</a>]. There was no obvious clinical benefit of L-arginine treatment, and the overall quality of the evidence was rated as poor. However, there is no clear consensus on the use of arginine for MELAS [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1">Controlled trials would be needed to establish whether <a class="drug drug_general" data-topicid="8883" href="/d/drug information/8883.html" rel="external">arginine</a> and citrulline treatment are beneficial in MELAS patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong> – The mechanism of the stroke-like episodes that occur in MELAS is not well defined.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One theory suggests that the stroke-like episodes result from ictal activity with neuronal hyperexcitability [<a href="#rid76">76,85,86</a>]. In support of this, stroke-like episodes in MELAS may be triggered by seizures, causing energy depletion, neuronal injury, and breakdown of the blood-brain barrier, which in turn leads to vasogenic edema [<a href="#rid77">77</a>]. Furthermore, observational data suggest that the clinical, radiologic, electroencephalographic, and neuropathologic findings associated with stroke-like episodes in MELAS are similar to those associated with epilepsy [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The vascular theory proposes that the stroke-like episodes result from both a mitochondrial cytopathy and a mitochondrial angiopathy [<a href="#rid88">88</a>]. The mitochondrial cytopathy results from energy failure due to defective mitochondrial energy production in brain tissue. The mitochondrial angiopathy is a result of abnormal mitochondria in the endothelial and smooth muscle cells of the cerebral arterioles and capillaries, which causes impairment of vasodilation and perfusion [<a href="#rid89">89,90</a>]. Some studies have suggested that stroke-like episodes are linked to deficiency of nitric oxide, which mediates vasodilation, or to low plasma levels of L-arginine or citrulline, which are precursors to nitric oxide [<a href="#rid80">80,89,91</a>]. However, convincing evidence of hypoperfusion or ischemia during stroke-like episodes is lacking, and the brain lesions accompanying the stroke-like episodes do not conform to vascular territories [<a href="#rid76">76</a>].</p><p></p><p class="headingAnchor" id="H199058726"><span class="h2">MNGIE</span><span class="headingEndMark"> — </span>Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a rare multisystem mitochondrial disorder caused by pathogenic variants of the nuclear <em>TYMP</em> gene that encodes thymidine phosphorylase. Absence of thymidine phosphorylase leads to toxic substrate (thymidine) accumulation in the plasma and imbalance in the nucleotide pool, causing dysfunctional mitochondrial DNA replication. In patients with residual thymidine phosphorylase activity of &lt;10 percent, life expectancy is limited to the fourth decade. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'MNGIE'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Evidence for efficacy of treatments for MNGIE is limited.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a few case reports, treatment with continuous peritoneal dialysis for up to three years was associated with substantial improvement in the debilitating gastrointestinal, autonomic, and neurologic manifestations of MNGIE [<a href="#rid92">92-94</a>]. Hemodialysis [<a href="#rid95">95</a>] and platelet infusions [<a href="#rid96">96</a>] can temporarily reduce the circulating toxic levels of thymidine but do not offer a long-term solution.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allogeneic hematopoietic stem cell transplantation (HSCT) is a potential disease-modifying treatments for MNGIE [<a href="#rid11">11,97,98</a>]. HSCT can restore thymidine phosphorylase activity and correct biochemical abnormalities, but mortality is high [<a href="#rid97">97,99</a>]. In a retrospective series of 24 patients with MNGIE who were treated with allogenic HSCT and followed for a median of approximately four years, only nine patients (38 percent) remained alive [<a href="#rid97">97</a>]. Among survivors, improvements in clinical manifestations of MNGIE (eg, gastrointestinal symptoms and peripheral neuropathy) were observed, but only after two years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enzyme replacement therapy with carrier erythrocyte-encapsulated thymidine phosphorylase, given in repeated cycles over more than two years, was associated with biochemical and clinical improvements in a case report [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orthotopic liver transplantation has been proposed as a treatment for MNGIE [<a href="#rid101">101,102</a>], as the liver is a source of thymidine phosphorylase [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1">Since evidence is sparse, treatment recommendations for MNGIE are based on expert opinion [<a href="#rid104">104,105</a>] and are individualized according to patient context. In younger patients who are early in the disease course, orthotopic liver transplantation may be considered. Peritoneal dialysis or enzyme replacement therapy (if available) can be used as a bridge to liver transplantation or offered to patients who are not eligible for liver transplantation. Further study is needed to determine if the benefits of HSCT outweigh the risks. Autologous HSCT with genetically modified stem cells may be an option in the future [<a href="#rid104">104</a>].</p><p></p><p class="headingAnchor" id="H741999068"><span class="h2">TK2 deficiency</span><span class="headingEndMark"> — </span>Pathogenic variants in the nuclear thymidine kinase 2 (<em>TK2</em>) gene cause depletion and multiple deletions of mitochondrial DNA, resulting in a progressive mitochondrial myopathy that usually begins in childhood.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Oral deoxynucleoside supplementation is a potential therapy for TK2 [<a href="#rid46">46,106</a>]. In an open-label study of 16 patients with TK2 deficiency, treatment with deoxynucleoside monophosphates and deoxynucleoside was associated with improved outcomes; survival and motor function were better than expected (compared with historical control patients) for five patients with severe early-onset disease, and clinical measures stabilized or improved for 11 childhood- and adult-onset patients [<a href="#rid107">107</a>]. Treatment was generally well tolerated; adverse effects included dose-dependent diarrhea (not leading to withdrawal of treatment) in 8 patients, and reversible increase in liver enzymes in 2 of 12 patients treated with deoxynucleoside. Further studies are needed to establish benefit.</p><p></p><p class="headingAnchor" id="H16"><span class="h1">GENETIC THERAPY</span><span class="headingEndMark"> — </span>Given the lack of effective pharmacologic agents for mitochondrial disorders, research into genetic strategies is ongoing. However, no strategy has been found to be conclusively effective. Therapeutic modification of the mitochondrial genome presents challenges beyond those seen in disorders of nuclear DNA [<a href="#rid108">108</a>]. In particular, heteroplasmy and the presence of multiple genomes in even single cells have complicated research in this field. (See  <a class="medical medical_review" href="/d/html/5148.html" rel="external">"Mitochondrial regulation and functions"</a>.)</p><p>Experimental approaches to gene therapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Delivery of a wildtype version of the defective gene using a viral vector for Leber hereditary optic neuropathy (LHON). (See <a class="local">'LHON'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing the ratio of wildtype DNA to mutant DNA (ie, to manipulate the level of heteroplasmy), a method known as "gene shifting" [<a href="#rid108">108,109</a>]. Evidence that exercise can alter the ratio of wildtype DNA to mutant DNA in muscle is presented above. (See <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Replacing the mutated mitochondrial DNA of the oocyte with a healthy mitochondrial genome from a donated oocyte. This can be accomplished by removing the cytoplasmic contents (including the abnormal mitochondria) from the mother's fertilized oocytes, transferring the nuclear content of these oocytes to a normal "enucleated" oocyte from a donor female prior to implantation [<a href="#rid110">110-112</a>]. The offspring would have all the nuclear genetic components of the parents but mitochondrial DNA from a donor female.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using mitochondrial-targeted nucleases (termed zinc finger nuclease and transcription activator-like effector nucleases) to selectively eliminate or correct mutated mitochondrial DNA [<a href="#rid113">113,114</a>]. In addition, germline genome editing using CRISPR/Cas9 system has been proposed to correct pathologic mutations in the nuclear genome [<a href="#rid113">113</a>].</p><p></p><p>All of these techniques are experimental, and most have been attempted only in animal models. Pre-implantation manipulation of embryos is controversial for ethical reasons and is not available in many areas.</p><p class="headingAnchor" id="H4101419909"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120961.html" rel="external">"Society guideline links: Mitochondrial disorders"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – There is no proven pharmacologic therapy for the primary mitochondrial disorders. The mainstay of treatment for patients with mitochondrial disease remains supportive. Issues that may require evaluation and intervention include respiratory failure, seizures, cardiomyopathy and conduction defects, ophthalmoplegia, ptosis, cataracts, hearing loss, diabetes mellitus, neurologic deficits (including dysarthria, dysphagia, weakness, spasticity, and/or ataxia), and cognitive impairment. (See <a class="local">'Supportive care and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplements</strong> – For most patients with mitochondrial disorders, we suggest treatment with a combination of antioxidant and cofactor supplements (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, these supplements are not established as effective for mitochondrial disorders. Our typical regimen for adults and adolescents is multivitamin, coenzyme Q10 (CoQ10; 400 mg daily), creatine (10 g daily), L-carnitine (levocarnitine) supplementation (990 mg daily in three divided doses), folate (1 mg daily), and B complex vitamins (eg, vitamin B-100 complex, one tablet daily). (See <a class="local">'Antioxidant and cofactor supplements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise</strong> – For patients with mitochondrial disorders who are able to participate in physical activity, routine, moderate-level aerobic exercise and regular mild resistance training may be beneficial. Options for aerobic exercise include walking, running, cycling, or swimming. (See <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ketogenic dietary therapy</strong> – This is an option for some patients with mitochondrial disorders, particularly those with concurrent epilepsy, and for patients with pyruvate dehydrogenase deficiency. (See <a class="local">'Ketogenic dietary therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of mitochondrial toxins</strong> – Patients with mitochondrial disorders should avoid certain drugs if possible, as listed above. (See <a class="local">'Potentially toxic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of specific mitochondrial disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CoQ10 deficiency</strong> – For patients with CoQ10 deficiency, we suggest high-dose oral CoQ10 treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'CoQ10 deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leigh syndrome</strong> – While there is no proven treatment for Leigh syndrome, patients with suspected Leigh syndrome should be treated with <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> (10 mg/kg) and <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> (20 mg/kg) daily, since biotin-thiamine-responsive basal ganglia disease (BTBGD) is a treatable condition that mimics Leigh syndrome. It is also reasonable to treat Leigh syndrome empirically with a CoQ10, <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">carnitine supplementation</a>, <a class="drug drug_general" data-topicid="9861" href="/d/drug information/9861.html" rel="external">riboflavin</a>, alpha-lipoic acid, creatine monohydrate, and <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>. (See <a class="local">'Leigh syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LHON</strong> – There is no proven effective treatment for Leber hereditary optic neuropathy (LHON). Idebenone is used by some experts and is approved in Europe for the treatment of visual impairment in adolescent and adult patients with LHON. (See <a class="local">'LHON'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MELAS</strong> – For patients with the syndrome of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) who have seizures, we treat with intravenous <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> (20 to 40 mg/kg, maximum 4500 mg) as our preferred antiseizure medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Other options are intravenous <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, or <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a>. The role of antiseizure medications in patients with MELAS but without seizures is unclear. Additionally, some experts treat stroke-like episodes with intravenous L-arginine or normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and dextrose-containing fluids. (See <a class="local">'MELAS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MNGIE</strong> – Evidence of efficacy is limited for treatments of mitochondrial neurogastrointestinal encephalopathy (MNGIE). For younger patients who are early in the disease course, orthotopic liver transplantation may be considered. Peritoneal dialysis or enzyme replacement therapy (if available) can be used as a bridge to liver transplantation or offered to patients who are not eligible for liver transplantation. (See <a class="local">'MNGIE'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TK2 deficiency</strong> – Oral deoxynucleoside supplementation is a potential therapy for thymidine kinase 2 (TK2) deficiency. (See <a class="local">'TK2 deficiency'</a> above.)</p><p></p><p class="headingAnchor" id="H984511396"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Angela Genge, MD, and Rami Massie, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kisler JE, Whittaker RG, McFarland R. Mitochondrial diseases in childhood: a clinical approach to investigation and management. Dev Med Child Neurol 2010; 52:422.</a></li><li><a class="nounderline abstract_t">Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2017; 19.</a></li><li><a class="nounderline abstract_t">Edmonds JL Jr. Surgical and anesthetic management of patients with mitochondrial dysfunction. Mitochondrion 2004; 4:543.</a></li><li><a class="nounderline abstract_t">Wahbi K, Bougouin W, Béhin A, et al. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. Eur Heart J 2015; 36:2886.</a></li><li><a class="nounderline abstract_t">Bau V, Zierz S. Update on chronic progressive external ophthalmoplegia. Strabismus 2005; 13:133.</a></li><li><a class="nounderline abstract_t">McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurol 2002; 1:343.</a></li><li><a class="nounderline abstract_t">Millhouse-Flourie TJ. Physical, occupational, respiratory, speech, equine and pet therapies for mitochondrial disease. Mitochondrion 2004; 4:549.</a></li><li class="breakAll">National Society of Genetic Counselors. www.nsgc.org/ (Accessed on August 31, 2016).</li><li><a class="nounderline abstract_t">Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; :CD004426.</a></li><li><a class="nounderline abstract_t">Esposito LA, Melov S, Panov A, et al. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci U S A 1999; 96:4820.</a></li><li><a class="nounderline abstract_t">Finsterer J. Clinical Therapeutic Management of Human Mitochondrial Disorders. Pediatr Neurol 2020; 113:66.</a></li><li><a class="nounderline abstract_t">DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34:265.</a></li><li><a class="nounderline abstract_t">Allen RJ, DiMauro S, Coulter DL, et al. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983; 13:679.</a></li><li><a class="nounderline abstract_t">Melegh B, Seress L, Bedekovics T, et al. Muscle carnitine acetyltransferase and carnitine deficiency in a case of mitochondrial encephalomyopathy. J Inherit Metab Dis 1999; 22:827.</a></li><li><a class="nounderline abstract_t">Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35:235.</a></li><li><a class="nounderline abstract_t">de Sousa CNS, da Silva Leite CMG, da Silva Medeiros I, et al. Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review. Metab Brain Dis 2019; 34:39.</a></li><li><a class="nounderline abstract_t">Artuch R, Vilaseca MA, Pineda M. Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease. J Inherit Metab Dis 1998; 21:837.</a></li><li><a class="nounderline abstract_t">Vallance HD, Koochin A, Branov J, et al. Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine. Mol Genet Metab Rep 2018; 15:130.</a></li><li><a class="nounderline abstract_t">Zhao JV, Burgess S, Fan B, Schooling CM. L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study. BMC Med 2022; 20:272.</a></li><li><a class="nounderline abstract_t">Du J, Miao M, Lu Z, et al. Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study. Nutr Metab Cardiovasc Dis 2022; 32:2579.</a></li><li><a class="nounderline abstract_t">Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010; 42:739.</a></li><li><a class="nounderline abstract_t">Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37:212.</a></li><li><a class="nounderline abstract_t">Muller W, Reimers CD, Berninger T. Coenzyme Q10 in ophthalmoplegia plus - a double blind cross over therapeutic trial. J Neurol Sci 1990; 98 Suppl:442.</a></li><li><a class="nounderline abstract_t">López-Lluch G, Del Pozo-Cruz J, Sánchez-Cuesta A, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition 2019; 57:133.</a></li><li><a class="nounderline abstract_t">Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20:1502.</a></li><li><a class="nounderline abstract_t">Komura K, Hobbiebrunken E, Wilichowski EK, Hanefeld FA. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003; 28:53.</a></li><li><a class="nounderline abstract_t">Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000; 55:1748.</a></li><li><a class="nounderline abstract_t">Ormazabal A, Casado M, Molero-Luis M, et al. Can folic acid have a role in mitochondrial disorders? Drug Discov Today 2015; 20:1349.</a></li><li><a class="nounderline abstract_t">Ramaekers VT, Häusler M, Opladen T, et al. Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 2002; 33:301.</a></li><li><a class="nounderline abstract_t">Garcia-Cazorla A, Quadros EV, Nascimento A, et al. Mitochondrial diseases associated with cerebral folate deficiency. Neurology 2008; 70:1360.</a></li><li><a class="nounderline abstract_t">Ramaekers V, Sequeira JM, Quadros EV. Clinical recognition and aspects of the cerebral folate deficiency syndromes. Clin Chem Lab Med 2013; 51:497.</a></li><li><a class="nounderline abstract_t">Foley AR, Menezes MP, Pandraud A, et al. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain 2014; 137:44.</a></li><li><a class="nounderline abstract_t">Tarnopolsky MA. Exercise as a therapeutic strategy for primary mitochondrial cytopathies. J Child Neurol 2014; 29:1225.</a></li><li><a class="nounderline abstract_t">Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006; 129:3402.</a></li><li><a class="nounderline abstract_t">Trenell MI, Sue CM, Kemp GJ, et al. Aerobic exercise and muscle metabolism in patients with mitochondrial myopathy. Muscle Nerve 2006; 33:524.</a></li><li><a class="nounderline abstract_t">Taivassalo T, Shoubridge EA, Chen J, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 2001; 50:133.</a></li><li><a class="nounderline abstract_t">Jeppesen TD. Aerobic Exercise Training in Patients With mtDNA-Related Mitochondrial Myopathy. Front Physiol 2020; 11:349.</a></li><li><a class="nounderline abstract_t">Cejudo P, Bautista J, Montemayor T, et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. Muscle Nerve 2005; 32:342.</a></li><li><a class="nounderline abstract_t">Shoubridge EA, Johns T, Karpati G. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum Mol Genet 1997; 6:2239.</a></li><li><a class="nounderline abstract_t">Murphy JL, Blakely EL, Schaefer AM, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131:2832.</a></li><li><a class="nounderline abstract_t">Zweers H, van Wegberg AMJ, Janssen MCH, Wortmann SB. Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety. Orphanet J Rare Dis 2021; 16:295.</a></li><li><a class="nounderline abstract_t">Qu C, Keijer J, Adjobo-Hermans MJW, et al. The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease. Int J Biochem Cell Biol 2021; 138:106050.</a></li><li><a class="nounderline abstract_t">Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004; 70:309.</a></li><li><a class="nounderline abstract_t">Huang L, Li H, Zhong J, et al. Efficacy and Safety of the Ketogenic Diet for Mitochondrial Disease With Epilepsy: A Prospective, Open-labeled, Controlled Study. Front Neurol 2022; 13:880944.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018; 3:175.</a></li><li><a class="nounderline abstract_t">Orsucci D, Ienco EC, Siciliano G, Mancuso M. Mitochondrial disorders and drugs: what every physician should know. Drugs Context 2019; 8:212588.</a></li><li><a class="nounderline abstract_t">Mirza NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011; 21:297.</a></li><li><a class="nounderline abstract_t">Mancuso M, Orsucci D, Filosto M, et al. Drugs and mitochondrial diseases: 40 queries and answers. Expert Opin Pharmacother 2012; 13:527.</a></li><li><a class="nounderline abstract_t">Finsterer J, Frank M. Propofol Is Mitochondrion-Toxic and May Unmask a Mitochondrial Disorder. J Child Neurol 2016; 31:1489.</a></li><li><a class="nounderline abstract_t">Rötig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356:391.</a></li><li><a class="nounderline abstract_t">Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65:606.</a></li><li><a class="nounderline abstract_t">Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 2012; 69:978.</a></li><li><a class="nounderline abstract_t">Wang Y, Hekimi S. The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review. J Cell Mol Med 2022; 26:4635.</a></li><li><a class="nounderline abstract_t">Sacconi S, Trevisson E, Salviati L, et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010; 20:44.</a></li><li><a class="nounderline abstract_t">Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57:515.</a></li><li><a class="nounderline abstract_t">Lalani SR, Vladutiu GD, Plunkett K, et al. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005; 62:317.</a></li><li><a class="nounderline abstract_t">Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology 2006; 66:253.</a></li><li><a class="nounderline abstract_t">Auré K, Benoist JF, Ogier de Baulny H, et al. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 2004; 63:727.</a></li><li><a class="nounderline abstract_t">Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358:2849.</a></li><li><a class="nounderline abstract_t">Tabarki B, Al-Shafi S, Al-Shahwan S, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 2013; 80:261.</a></li><li><a class="nounderline abstract_t">Alfadhel M, Almuntashri M, Jadah RH, et al. Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis 2013; 8:83.</a></li><li><a class="nounderline abstract_t">Eichler FS, Swoboda KJ, Hunt AL, et al. Case 38-2017. A 20-Year-Old Woman with Seizures and Progressive Dystonia. N Engl J Med 2017; 377:2376.</a></li><li><a class="nounderline abstract_t">Baertling F, Rodenburg RJ, Schaper J, et al. A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry 2014; 85:257.</a></li><li><a class="nounderline abstract_t">Poincenot L, Pearson AL, Karanjia R. Demographics of a Large International Population of Patients Affected by Leber's Hereditary Optic Neuropathy. Ophthalmology 2020; 127:679.</a></li><li><a class="nounderline abstract_t">Carelli V, Carbonelli M, de Coo IF, et al. International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy. J Neuroophthalmol 2017; 37:371.</a></li><li><a class="nounderline abstract_t">Carelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011; 134:e188.</a></li><li><a class="nounderline abstract_t">Zhao X, Zhang Y, Lu L, Yang H. Therapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy. Curr Eye Res 2020; 45:1315.</a></li><li><a class="nounderline abstract_t">Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134:2677.</a></li><li><a class="nounderline abstract_t">Feuer WJ, Schiffman JC, Davis JL, et al. Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results. Ophthalmology 2016; 123:558.</a></li><li><a class="nounderline abstract_t">Wan X, Pei H, Zhao MJ, et al. Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy. Sci Rep 2016; 6:21587.</a></li><li><a class="nounderline abstract_t">Guy J, Feuer WJ, Davis JL, et al. Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results. Ophthalmology 2017; 124:1621.</a></li><li><a class="nounderline abstract_t">Vignal C, Uretsky S, Fitoussi S, et al. Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic Neuropathy. Ophthalmology 2018; 125:945.</a></li><li><a class="nounderline abstract_t">Biousse V, Newman NJ, Yu-Wai-Man P, et al. Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study. J Neuroophthalmol 2021; 41:309.</a></li><li><a class="nounderline abstract_t">Yu-Wai-Man P, Newman NJ, Carelli V, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med 2020; 12.</a></li><li><a class="nounderline abstract_t">Newman N, Yu-Wai-Man P, Carelli V, et al. The phase III REFLECT trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON) (P17-12.002). Neurology 2022; 98.</a></li><li><a class="nounderline abstract_t">Ng YS, Bindoff LA, Gorman GS, et al. Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res 2019; 4:201.</a></li><li><a class="nounderline abstract_t">Fryer RH, Bain JM, De Vivo DC. Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options. Pediatr Neurol 2016; 56:59.</a></li><li><a class="nounderline abstract_t">Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015; 17:689.</a></li><li><a class="nounderline abstract_t">Koenig MK, Emrick L, Karaa A, et al. Recommendations for the Management of Strokelike Episodes in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike Episodes. JAMA Neurol 2016; 73:591.</a></li><li><a class="nounderline abstract_t">Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64:710.</a></li><li><a class="nounderline abstract_t">El-Hattab AW, Emrick LT, Hsu JW, et al. Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation. Mol Genet Metab 2016; 117:407.</a></li><li><a class="nounderline abstract_t">Koga Y, Povalko N, Inoue E, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol 2018; 265:2861.</a></li><li><a class="nounderline abstract_t">Stefanetti RJ, Ng YS, Errington L, et al. l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review. Neurology 2022; 98:e2318.</a></li><li><a class="nounderline abstract_t">Hirata K, Akita Y, Povalko N, et al. Effect of L-arginine on synaptosomal mitochondrial function. Brain Dev 2008; 30:238.</a></li><li><a class="nounderline abstract_t">Iizuka T, Sakai F, Suzuki N, et al. Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 2002; 59:816.</a></li><li><a class="nounderline abstract_t">Tetsuka S, Ogawa T, Hashimoto R, Kato H. Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS. Metab Brain Dis 2021; 36:2181.</a></li><li><a class="nounderline abstract_t">Ng YS, Lax NZ, Blain AP, et al. Forecasting stroke-like episodes and outcomes in mitochondrial disease. Brain 2022; 145:542.</a></li><li><a class="nounderline abstract_t">Gilchrist JM, Sikirica M, Stopa E, Shanske S. Adult-onset MELAS. Evidence for involvement of neurons as well as cerebral vasculature in strokelike episodes. Stroke 1996; 27:1420.</a></li><li><a class="nounderline abstract_t">El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015; 116:4.</a></li><li><a class="nounderline abstract_t">Zhao Y, Yu X, Ji K, et al. Reversible cerebral artery constriction accompanied with stroke-like episode in MELAS: A case series. J Neurol Sci 2022; 441:120345.</a></li><li><a class="nounderline abstract_t">Naini A, Kaufmann P, Shanske S, et al. Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox". J Neurol Sci 2005; 229-230:187.</a></li><li><a class="nounderline abstract_t">Yavuz H, Ozel A, Christensen M, et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol 2007; 64:435.</a></li><li><a class="nounderline abstract_t">Sivadasan A, Muthusamy K, Patil AK, et al. Pearls &amp; Oy-sters: Mitochondrial neurogastrointestinal encephalomyopathy: Diagnosis and response to peritoneal dialysis. Neurology 2016; 86:e147.</a></li><li><a class="nounderline abstract_t">Ariaudo C, Daidola G, Ferrero B, et al. Mitochondrial neurogastrointestinal encephalomyopathy treated with peritoneal dialysis and bone marrow transplantation. J Nephrol 2015; 28:125.</a></li><li><a class="nounderline abstract_t">Spinazzola A, Marti R, Nishino I, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002; 277:4128.</a></li><li><a class="nounderline abstract_t">Lara MC, Weiss B, Illa I, et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 2006; 67:1461.</a></li><li><a class="nounderline abstract_t">Halter JP, Michael W, Schüpbach M, et al. Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain 2015; 138:2847.</a></li><li><a class="nounderline abstract_t">Bax BE. Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment. J Transl Genet Genom 2020; 4:1.</a></li><li><a class="nounderline abstract_t">Filosto M, Scarpelli M, Tonin P, et al. Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol 2012; 259:2699.</a></li><li><a class="nounderline abstract_t">Bax BE, Bain MD, Scarpelli M, et al. Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology 2013; 81:1269.</a></li><li><a class="nounderline abstract_t">D'Angelo R, Rinaldi R, Carelli V, et al. ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. Neurol Sci 2016; 37:1149.</a></li><li><a class="nounderline abstract_t">De Giorgio R, Pironi L, Rinaldi R, et al. Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Ann Neurol 2016; 80:448.</a></li><li><a class="nounderline abstract_t">Boschetti E, D'Alessandro R, Bianco F, et al. Liver as a source for thymidine phosphorylase replacement in mitochondrial neurogastrointestinal encephalomyopathy. PLoS One 2014; 9:e96692.</a></li><li><a class="nounderline abstract_t">López-Gómez C, Cámara Y, Hirano M, et al. 232nd ENMC international workshop: Recommendations for treatment of mitochondrial DNA maintenance disorders. 16 - 18 June 2017, Heemskerk, The Netherlands. Neuromuscul Disord 2022; 32:609.</a></li><li><a class="nounderline abstract_t">Hirano M, Carelli V, De Giorgio R, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network. J Inherit Metab Dis 2021; 44:376.</a></li><li><a class="nounderline abstract_t">Tinker RJ, Lim AZ, Stefanetti RJ, McFarland R. Current and Emerging Clinical Treatment in Mitochondrial Disease. Mol Diagn Ther 2021; 25:181.</a></li><li><a class="nounderline abstract_t">Domínguez-González C, Madruga-Garrido M, Mavillard F, et al. Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy. Ann Neurol 2019; 86:293.</a></li><li><a class="nounderline abstract_t">Adhya S, Mahato B, Jash S, et al. Mitochondrial gene therapy: The tortuous path from bench to bedside. Mitochondrion 2011; 11:839.</a></li><li><a class="nounderline abstract_t">Scarpelli M, Cotelli MS, Mancuso M, et al. Current options in the treatment of mitochondrial diseases. Recent Pat CNS Drug Discov 2010; 5:203.</a></li><li><a class="nounderline abstract_t">Tachibana M, Amato P, Sparman M, et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493:627.</a></li><li><a class="nounderline abstract_t">Tachibana M, Sparman M, Mitalipov S. Chromosome transfer in mature oocytes. Nat Protoc 2010; 5:1138.</a></li><li><a class="nounderline abstract_t">Paull D, Emmanuele V, Weiss KA, et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature 2013; 493:632.</a></li><li><a class="nounderline abstract_t">Yu-Wai-Man P. Genetic manipulation for inherited neurodegenerative diseases: myth or reality? Br J Ophthalmol 2016; 100:1322.</a></li><li><a class="nounderline abstract_t">Jo A, Ham S, Lee GH, et al. Efficient Mitochondrial Genome Editing by CRISPR/Cas9. Biomed Res Int 2015; 2015:305716.</a></li></ol></div><div id="topicVersionRevision">Topic 5149 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163433" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mitochondrial diseases in childhood: a clinical approach to investigation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749475" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120412" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgical and anesthetic management of patients with mitochondrial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224072" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251143" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Update on chronic progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849395" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The neurology of mitochondrial DNA disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120413" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Physical, occupational, respiratory, speech, equine and pet therapies for mitochondrial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120413" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Physical, occupational, respiratory, speech, equine and pet therapies for mitochondrial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513923" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment for mitochondrial disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220377" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mitochondrial disease in mouse results in increased oxidative stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33053453" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical Therapeutic Management of Human Mitochondrial Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16810684" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Approaches to the treatment of mitochondrial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6881930" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10518284" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Muscle carnitine acetyltransferase and carnitine deficiency in a case of mitochondrial encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080429" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30467770" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870209" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30023305" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36045366" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36155150" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20886510" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A randomized trial of coenzyme Q10 in mitochondrial disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9208260" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Coenzyme Q10 in ophthalmoplegia plus - a double blind cross over therapeutic trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153575" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390662" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12657421" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113239" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A placebo-controlled crossover trial of creatine in mitochondrial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26183769" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Can folic acid have a role in mitochondrial disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12571785" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413591" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mitochondrial diseases associated with cerebral folate deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314536" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical recognition and aspects of the cerebral folate deficiency syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24253200" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25008908" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Exercise as a therapeutic strategy for primary mitochondrial cytopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815877" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16372322" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aerobic exercise and muscle metabolism in patients with mitochondrial myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11506394" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32508662" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Aerobic Exercise Training in Patients With mtDNA-Related Mitochondrial Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15962332" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Exercise training in mitochondrial myopathy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361028" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984605" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Resistance training in patients with single, large-scale deletions of mitochondrial DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217336" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34298163" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769489" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35979062" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and Safety of the Ketogenic Diet for Mitochondrial Disease With Epilepsy: A Prospective, Open-labeled, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29881797" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31391854" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mitochondrial disorders and drugs: what every physician should know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21278619" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22292617" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Drugs and mitochondrial diseases: 40 queries and answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27488955" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Propofol Is Mitochondrion-Toxic and May Unmask a Mitochondrial Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972372" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116126" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490322" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Heterogeneity of coenzyme Q10 deficiency: patient study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35985679" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945282" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502923" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710863" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434667" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Coenzyme Q10 deficiency and isolated myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15326254" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Progression despite replacement of a myopathic form of coenzyme Q10 defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579827" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269594" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23742248" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29236641" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Case 38-2017. A 20-Year-Old Woman with Seizures and Progressive Dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772060" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A guide to diagnosis and treatment of Leigh syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932089" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Demographics of a Large International Population of Patients Affected by Leber's Hereditary Optic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28991104" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810891" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Idebenone treatment in Leber's hereditary optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32111141" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Therapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788663" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606867" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892229" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28647203" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29426586" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34415265" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33298565" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The phase III REFLECT trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON) (P17-12.002)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090171" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Consensus-based statements for the management of mitochondrial stroke-like episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797286" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25503498" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26954033" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recommendations for the Management of Strokelike Episodes in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike Episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728297" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : L-arginine improves the symptoms of strokelike episodes in MELAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26851065" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30269300" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35428733" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : l-Arginine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889473" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of L-arginine on synaptosomal mitochondrial function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12297560" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34118021" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34927673" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Forecasting stroke-like episodes and outcomes in mitochondrial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8711813" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Adult-onset MELAS. Evidence for involvement of neurons as well as cerebral vasculature in strokelike episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26095523" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35940028" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Reversible cerebral artery constriction accompanied with stroke-like episode in MELAS: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760638" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353390" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27044617" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pearls&amp;Oy-sters: Mitochondrial neurogastrointestinal encephalomyopathy: Diagnosis and response to peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599829" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Mitochondrial neurogastrointestinal encephalomyopathy treated with peritoneal dialysis and bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733540" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Altered thymidine metabolism due to defects of thymidine phosphorylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971699" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Infusion of platelets transiently reduces nucleoside overload in MNGIE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264513" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32914088" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Mitochondrial neurogastrointestinal encephalomyopathy: approaches to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711161" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966250" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27007276" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421916" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24802030" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Liver as a source for thymidine phosphorylase replacement in mitochondrial neurogastrointestinal encephalomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35641351" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : 232nd ENMC international workshop: Recommendations for treatment of mitochondrial DNA maintenance disorders. 16 - 18 June 2017, Heemskerk, The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32898308" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33646563" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Current and Emerging Clinical Treatment in Mitochondrial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31125140" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704735" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Mitochondrial gene therapy: The tortuous path from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20722626" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Current options in the treatment of mitochondrial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23103867" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Towards germline gene therapy of inherited mitochondrial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20539289" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Chromosome transfer in mature oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254936" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002113" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Genetic manipulation for inherited neurodegenerative diseases: myth or reality?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26448933" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Efficient Mitochondrial Genome Editing by CRISPR/Cas9.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
